{"id":46404,"date":"2022-07-20T22:01:58","date_gmt":"2022-07-20T20:01:58","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/exicure-inc-regains-compliance-with-nasdaq-minimum-bid-price-requirement\/"},"modified":"2022-07-20T22:01:58","modified_gmt":"2022-07-20T20:01:58","slug":"exicure-inc-regains-compliance-with-nasdaq-minimum-bid-price-requirement","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/exicure-inc-regains-compliance-with-nasdaq-minimum-bid-price-requirement\/","title":{"rendered":"Exicure, Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement"},"content":{"rendered":"
\n

CHICAGO–(BUSINESS WIRE)–Exicure, Inc. (Nasdaq: XCUR), an early-stage biotechnology company focused on the development of next generation nucleic acid therapies targeting RNA to address both genetic and non-genetic neurological disorders and hair loss disorders, today announced that on July 19, 2022, it received a letter from the Office of General Counsel of The Nasdaq Stock Market LLC informing it that Nasdaq has confirmed that the Company has regained compliance with the $1.00 per share minimum bid price requirement pursuant to Nasdaq Listing Rule 5450(a)(1) and that the Company is in compliance with all applicable listing standards. Accordingly, the scheduled hearing before the Nasdaq Hearings Panel has been cancelled and the Company\u2019s Common Stock will continue to be listed and traded on The Nasdaq Capital Market.\n<\/p>\n

<\/a><\/p>\n

\nAbout Exicure<\/b>\n<\/p>\n

\nExicure, Inc. is an early-stage biotechnology company developing nucleic acid therapies targeting ribonucleic acid against validated targets to neurological disorders and hair loss. The team includes a diverse scientific group with expertise in nucleic acid chemistry, drug development and neuroscience. Headquartered in Chicago, Illinois, the Company conducts its discovery and development efforts in-house with a dedicated 30,000 square foot facility, including rapid and automated high throughput nucleic acid synthesis and screening. For further information, see www.exicuretx.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia:<\/b>
Karen Sharma
\n
MacDougall
\n
781-235-3060
\n
ksharma@macdougall.bio<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

CHICAGO–(BUSINESS WIRE)–Exicure, Inc. (Nasdaq: XCUR), an early-stage biotechnology company focused on the development of next generation nucleic acid therapies targeting RNA to address both genetic and non-genetic neurological disorders and hair loss disorders, today announced that on July 19, 2022, it received a letter from the Office of General Counsel of The Nasdaq Stock Market … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-46404","6":"format-standard","7":"category-industry"},"yoast_head":"\nExicure, Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/exicure-inc-regains-compliance-with-nasdaq-minimum-bid-price-requirement\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Exicure, Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"CHICAGO–(BUSINESS WIRE)–Exicure, Inc. (Nasdaq: XCUR), an early-stage biotechnology company focused on the development of next generation nucleic acid therapies targeting RNA to address both genetic and non-genetic neurological disorders and hair loss disorders, today announced that on July 19, 2022, it received a letter from the Office of General Counsel of The Nasdaq Stock Market ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/exicure-inc-regains-compliance-with-nasdaq-minimum-bid-price-requirement\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-20T20:01:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220720005754\/en\/651600\/21\/Exicure_Logo_FINAL_Full_Color-072515.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exicure-inc-regains-compliance-with-nasdaq-minimum-bid-price-requirement\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exicure-inc-regains-compliance-with-nasdaq-minimum-bid-price-requirement\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Exicure, Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement\",\"datePublished\":\"2022-07-20T20:01:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exicure-inc-regains-compliance-with-nasdaq-minimum-bid-price-requirement\\\/\"},\"wordCount\":223,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exicure-inc-regains-compliance-with-nasdaq-minimum-bid-price-requirement\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220720005754\\\/en\\\/651600\\\/21\\\/Exicure_Logo_FINAL_Full_Color-072515.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exicure-inc-regains-compliance-with-nasdaq-minimum-bid-price-requirement\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exicure-inc-regains-compliance-with-nasdaq-minimum-bid-price-requirement\\\/\",\"name\":\"Exicure, Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exicure-inc-regains-compliance-with-nasdaq-minimum-bid-price-requirement\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exicure-inc-regains-compliance-with-nasdaq-minimum-bid-price-requirement\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220720005754\\\/en\\\/651600\\\/21\\\/Exicure_Logo_FINAL_Full_Color-072515.jpg\",\"datePublished\":\"2022-07-20T20:01:58+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exicure-inc-regains-compliance-with-nasdaq-minimum-bid-price-requirement\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exicure-inc-regains-compliance-with-nasdaq-minimum-bid-price-requirement\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exicure-inc-regains-compliance-with-nasdaq-minimum-bid-price-requirement\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220720005754\\\/en\\\/651600\\\/21\\\/Exicure_Logo_FINAL_Full_Color-072515.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220720005754\\\/en\\\/651600\\\/21\\\/Exicure_Logo_FINAL_Full_Color-072515.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exicure-inc-regains-compliance-with-nasdaq-minimum-bid-price-requirement\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Exicure, Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Exicure, Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/exicure-inc-regains-compliance-with-nasdaq-minimum-bid-price-requirement\/","og_locale":"en_US","og_type":"article","og_title":"Exicure, Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement - Pharma Trend","og_description":"CHICAGO–(BUSINESS WIRE)–Exicure, Inc. (Nasdaq: XCUR), an early-stage biotechnology company focused on the development of next generation nucleic acid therapies targeting RNA to address both genetic and non-genetic neurological disorders and hair loss disorders, today announced that on July 19, 2022, it received a letter from the Office of General Counsel of The Nasdaq Stock Market ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/exicure-inc-regains-compliance-with-nasdaq-minimum-bid-price-requirement\/","og_site_name":"Pharma Trend","article_published_time":"2022-07-20T20:01:58+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220720005754\/en\/651600\/21\/Exicure_Logo_FINAL_Full_Color-072515.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/exicure-inc-regains-compliance-with-nasdaq-minimum-bid-price-requirement\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/exicure-inc-regains-compliance-with-nasdaq-minimum-bid-price-requirement\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Exicure, Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement","datePublished":"2022-07-20T20:01:58+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/exicure-inc-regains-compliance-with-nasdaq-minimum-bid-price-requirement\/"},"wordCount":223,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/exicure-inc-regains-compliance-with-nasdaq-minimum-bid-price-requirement\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220720005754\/en\/651600\/21\/Exicure_Logo_FINAL_Full_Color-072515.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/exicure-inc-regains-compliance-with-nasdaq-minimum-bid-price-requirement\/","url":"https:\/\/pharma-trend.com\/en\/exicure-inc-regains-compliance-with-nasdaq-minimum-bid-price-requirement\/","name":"Exicure, Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/exicure-inc-regains-compliance-with-nasdaq-minimum-bid-price-requirement\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/exicure-inc-regains-compliance-with-nasdaq-minimum-bid-price-requirement\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220720005754\/en\/651600\/21\/Exicure_Logo_FINAL_Full_Color-072515.jpg","datePublished":"2022-07-20T20:01:58+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/exicure-inc-regains-compliance-with-nasdaq-minimum-bid-price-requirement\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/exicure-inc-regains-compliance-with-nasdaq-minimum-bid-price-requirement\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/exicure-inc-regains-compliance-with-nasdaq-minimum-bid-price-requirement\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220720005754\/en\/651600\/21\/Exicure_Logo_FINAL_Full_Color-072515.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220720005754\/en\/651600\/21\/Exicure_Logo_FINAL_Full_Color-072515.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/exicure-inc-regains-compliance-with-nasdaq-minimum-bid-price-requirement\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Exicure, Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46404","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=46404"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46404\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=46404"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=46404"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=46404"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}